Screen Shot 2018-06-07 at 1.42.50 PM

The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke

Program Overview

This CME/CNE program is derived from content presented at the National Lipid Association 2018 Scientific Sessions in Las Vegas, Nevada. The five expert faculty, led by Dr. Alan S. Brown, will review best practices for assessing the risk of cardiovascular disease (CVD). Recently released data, including the results of the ODYSSEY and FOURIER trials, will be outlined followed by a debate of the clinical implications of these studies in modern day medicine. The faculty will utilize a case-based approach to relay optimal strategies for treating and managing CVD patients through the engagement of the interprofessional team, particularly to prevent heart attack and stroke. Upon completion of this educational activity, learners will gain insight into how to better provide personalized, comprehensive care for patients with dyslipidemia.

Target Audience

Cardiologists, endocrinologists, primary care physicians, nurse practitioners, nurses, pharmacists, and other healthcare professionals involved in the management of patients with or at risk for cardiovascular disease.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

1. Recognize the accurate assessment of cardiovascular disease risk across all patient populations
2. Analyze the clinical trial and real world data that supports the role of PCSK9 therapeutics for the prevention of heart attack and stroke
3. Appraise the use of PCSK9 therapeutics through case studies
4. Discuss strategies to improve the knowledge, skills or performance of the healthcare team


Brown Head Shot

 Alan S. Brown, MD (Course Chair)
Director, Division of Cardiology
Advocate Lutheran General Hospital
President-Elect, National Lipid Association
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch Medical School
Park Ridge, Illinois

Giugliano Headshot

Robert P. Giugliano, MD, SM
Physician, CV Medicine
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts





Peter H. Jones, MD
Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, Texas





Soffer HeadshotDaniel E. Soffer, MD
Clinical Associate Professor of Medicine
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, Pennsylvania



Underberg #6James A. Underberg, MD, MS
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
President, National Lipid Association
New York, New York




Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

FacultyRelationship Identified With:
Alan S. Brown, MDConsultant/Advisor: Akcea Therapeutics; Amgen Inc.; Kowa Pharmaceuticals America, Inc.; Regeneron PharmaceuticalsSpeaker’s Bureau: Amgen Inc.; Regeneron Pharmaceuticals; Sanofi-aventis U.S. LLC
Robert P. Giugliano, MDConsultant/Advisor: Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVS Caremark; Daiichi Sankyo Company, Limited; GlaxoSmithKline; Lexicon Pharmaceuticals; Merck & Co.; Portola Pharmaceuticals, Inc.; Pfizer Inc.Grant/Research Support: Amgen Inc.
Peter H. Jones, MDConsultant/Advisor: Amgen, Inc.; Regeneron Pharmaceuticals; Sanofi-aventis U.S. LLC
Daniel E. Soffer, MD Consultant/Advisor: Amgen Inc.; Akcea TherapeuticsGrant/Research Support: Akcea Therapeutics; Amgen Inc.; AstraZeneca; Esperion Therapeutics; Ionis Pharmaceuticals; Kowa Pharmaceuticals America, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals; Regenix; Sanofi-aventis U.S. LLCSpeaker’s Bureau: Akcea Therapeutics
James A. Underberg, MD, MSConsultant/Advisor: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Invitae Corporation; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLCSpeaker’s Bureau: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Regeneron Pharmaceuticals; sanofi-aventis U.S. LLCGrant/Research Support: Aegerion Pharmaceuticals, Inc.; Pfizer 

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski; Chelsey Benedek and and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour.

Financial Support

This activity has been supported by an independent educational grant from Sanofi US Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi US Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].